Paintaud G, Bechtel Y, Brientini M P, Miguet J P, Bechtel P R
Department of Clinical Pharmacology, Hôpital Jean-Minjoz, Besançon University Hospital, France.
Therapie. 1996 Jul-Aug;51(4):384-9.
Although the liver is the main site of drug metabolism, conflicting results have been reported on drug elimination during liver diseases. Drug metabolism may depend on histological changes in the liver (acute or chronic hepatitis, cirrhosis) but may also depend on their origin (viral, toxic or immunological). Drug metabolism is also influenced by the severity of liver dysfunction. Cytochrome P450 isozymes and conjugation pathways may be differently affected by these conditions, and specific probe drugs have to be used in order to study the effect of diseases on each enzyme of drug metabolism. Probe-based assays must be validated during disease, since the pharmacokinetics of the parent drug and/or of its metabolites may be altered. Because of these limitations, therapeutic drug monitoring may be the most reliable way to adjust drug dosing at present.
尽管肝脏是药物代谢的主要场所,但关于肝脏疾病期间药物消除的报道结果相互矛盾。药物代谢可能取决于肝脏的组织学变化(急性或慢性肝炎、肝硬化),但也可能取决于其病因(病毒、毒性或免疫性)。药物代谢还受肝功能障碍严重程度的影响。细胞色素P450同工酶和结合途径可能受到这些情况的不同影响,为了研究疾病对药物代谢各酶的影响,必须使用特定的探针药物。基于探针的检测方法在疾病期间必须进行验证,因为母体药物和/或其代谢物的药代动力学可能会改变。由于这些限制,目前治疗药物监测可能是调整药物剂量最可靠的方法。